GBT Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (4 okt 2022 @ 22:00):

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD)...

Stats
Dagens volum	3.28M
Gjennomsnittsvolum	0
Markedsverdi	0.00
EPS	$0 ( 2022-11-02 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-14.08
ATR14	$0.890 (1.30%)

Insider Trading

Date	Person	Action	Amount	type
2022-10-05	Perry Mark L	Sell	5 600	Stock Option (Right to Buy)
2022-10-05	Patrick Deval L	Sell	5 600	Stock Option (Right to Buy)
2022-10-05	Morrison Scott W	Sell	5 600	Stock Option (Right to Buy)
2022-10-05	Thompson Alexis A.	Sell	3 600	Restricted Stock Units
2022-10-05	Yarno Wendy L	Sell	30 000	Stock Option (Right to Buy)

INSIDER POWER
-60.36
Last 100 transactions
Buy: 278 284 \| Sell: 1 075 911

Volum Korrelasjon

Lang: 0.35 (neutral)

Kort: 0.93 (very strong)

Signal:(77.112) Expect same movement, but be aware

Global Blood Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Global Blood Korrelasjon - Valuta/Råvare

0.94
( very strong )

0.92
( very strong )

-0.79
( moderate negative )

0.83
( strong )

0.23
( neutral )

-0.61
( weak negative )

Global Blood Økonomi

Annual	2021
Omsetning:	$194.75M
Bruttogevinst:	$191.43M (98.30 %)
EPS:	$-4.82

FY	2021
Omsetning:	$194.75M
Bruttogevinst:	$191.43M (98.30 %)
EPS:	$-4.82

FY	2020
Omsetning:	$123.80M
Bruttogevinst:	$121.82M (98.40 %)
EPS:	$-4.04

FY	2019
Omsetning:	$2.11M
Bruttogevinst:	$2.06M (97.72 %)
EPS:	$-4.57

Financial Reports:

No articles found.

Global Blood

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.